Venture-backed Lorus Therapeutics to raise $17 mln in public offering
Clinical-stage biotechnology company Lorus Therapeutics Inc (TSX: LOR) has filed a preliminary prospectus for an overnight marketed public offering of common shares for about $17 million. The net proceeds will be used to develop the company's cancer-related drug therapies, fund its manufacturing program, support ongoing research and development, and for other general and corporate working capital purposes. Based in Toronto, Lorus is a portfolio company of Canadian life sciences-focused venture capital firm Lumira Capital, Pinetree Capital and other investors.
27 March 2014•4 mins read
